Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02439346 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
A Phase 1 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02439346 is a Phase 1 study that was terminated before completion, run by Bayer. The registered enrollment target is 15 participants.
The verdict
NCT02439346, a Phase 1 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with advanced solid tumors.
Interventions
- DRUG BAY1143269 tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-06-15 |
| Est. Completion | 2017-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02439346
The ClinicalTrials.gov registry entry for NCT02439346 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY1143269 tablet is the first listed.
NCT02439346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02439346 about?
NCT02439346 is a clinical study titled "Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel". Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with advanced solid tumors.
What is the current status of trial NCT02439346?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-06-15. Estimated completion is 2017-04-24.
What interventions are being tested in trial NCT02439346?
The interventions under investigation include: BAY1143269 tablet (DRUG).
Who is sponsoring clinical trial NCT02439346?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.